Trial Profile

Comparative Effectiveness Study of Real-world Control of TRK Fusion Positive Cancer With Patients From Larotrectinib (Vitrakvi) Clinical Trials

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 01 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Larotrectinib (Primary)
Indications Carcinoma; Colorectal cancer; Non-small cell lung cancer; Salivary gland cancer; Sarcoma; Thyroid cancer
Focus Therapeutic Use
Acronyms VICTORIA
Sponsors Bayer

Most Recent Events

04 Jun 2024 Results (n=164) comparing Larotrectinib with with real-world data from non-TRK inhibitor therapies in patients with TRK fusion cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology
13 Nov 2023 Status changed from active, no longer recruiting to completed.
12 Oct 2023 Planned End Date changed from 31 Aug 2023 to 30 Nov 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com